Viking Therapeutics Stock Swings Wildly After Weight-Loss Drug Data
Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's what you need to know.
Viking Therapeutics (VKTX) stock jumped 6% out of the gate Monday, but was last seen notably lower. The volatility comes after the biopharmaceutical company reported positive new clinical data for its weight-loss pill, VK2735.
The data released by Viking showed that adults taking the highest dosage of the oral VK2735 tablet lost an average of 8.2% of their body weight in just four weeks, or 6.8% more than those that received a placebo.
"We believe the VENTURE data demonstrate VK2735's promising efficacy and tolerability profile through 13 weeks of weekly dosing and support our belief that less frequent dosing regimens may provide effective maintenance of weight control," said Viking CEO Brian Lian, Ph.D., in a statement.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
"The updated oral Phase 1 study results continue to demonstrate an encouraging tolerability profile and promising signs of clinical activity at doses of up to 100 milligrams daily," the executive added. "We believe the durable effects observed following 28 days of dosing suggest potential opportunities to introduce lower dose regimens following an initial induction of weight loss."
Lian noted that Viking plans to move forward on the clinical path with the Food and Drug Administration (FDA) later this year for an injectable version of VK2735 and that they expect to initiate a Phase 2 study of the oral tablet formation by the end of the fourth quarter.
Is Viking Therapeutics stock a buy, sell or hold?
It's been a volatile year for Viking Therapeutics stock, though good news on the weight-loss-drug front has the healthcare stock up 260% since the start of January. And Wall Street sees even more upside for VKTX.
According to S&P Global Market Intelligence, the consensus analyst target price for the mid-cap stock is $112.85, representing implied upside of nearly 55% to current levels. Additionally, the consensus recommendation is Strong Buy.
Financial services firm William Blair has an Outperform rating (equivalent to a Buy) on VKTX and gives it a current fair value of $96 per share.
"From a competitive advantage perspective, VK2735's status as a Phase III-ready asset, coupled with the ability to formulate into an oral route of administration (tablet formulation), along with an amylin program that is on track to enter Phase I development next year, offers a unique set of attractive characteristics in the lens of big pharma," says William Blair analyst Andy Hsieh.
The analyst acknowledges that it is "risky to base our investment thesis on an eventual takeout, the prospect is reasonably high given Viking's clinical differentiation, combined with the large total addressable market of chronic metabolic conditions."
Related content
Get Kiplinger Today newsletter — free
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.
Joey Solitro is a freelance financial journalist at Kiplinger with more than a decade of experience. A longtime equity analyst, Joey has covered a range of industries for media outlets including The Motley Fool, Seeking Alpha, Market Realist, and TipRanks. Joey holds a bachelor's degree in business administration.
-
TJX Stock: Wall Street Stays Bullish After Earnings
TJX stock is trading lower Wednesday despite the TJ Maxx owner's beat-and-raise quarter, but analysts aren't worried. Here's why.
By Joey Solitro Published
-
Beware Three Medicare Open Enrollment Scams
Crooks are perfecting Medicare Open Enrollment scams to try to steal your money or personal information.
By Donna LeValley Published
-
TJX Stock: Wall Street Stays Bullish After Earnings
TJX stock is trading lower Wednesday despite the TJ Maxx owner's beat-and-raise quarter, but analysts aren't worried. Here's why.
By Joey Solitro Published
-
Target Is the Worst S&P 500 Stock After Earnings. Here's Why
Target stock is down big after the retailer missed expectations for its third quarter and slashed its full-year outlook. Here's what Wall Street is saying.
By Joey Solitro Published
-
For a More Secure Retirement, Build in Some 'Safe Money'
To solidify your retirement plan, write it down, reduce your market risk and allocate more safe money into your plan for income.
By Kevin Wade Published
-
Five Steps to a Mindfully Fearless Career
If, like many women, you're struggling with imposter syndrome, try developing an athlete's winning mindset. It's as simple as facing one small fear every day.
By Lisa Cregan Published
-
Stock Market Today: Stocks Rally Despite Rising Geopolitical Tension
The main indexes were mixed on Tuesday but closed well off their lows after an early flight to safety.
By David Dittman Published
-
What's at Stake for Alphabet as DOJ Eyes Google's Chrome
Alphabet is higher Tuesday even as antitrust officials at the DOJ support forcing Google to sell its popular web browser. Here's what you need to know.
By Joey Solitro Published
-
Lowe's Stock Is Falling After Earnings. Here's Why
Lowe's stock is lower Tuesday as Wall Street weighs a beat-and-raise quarter against declining revenue. This is what you need to know.
By Joey Solitro Published
-
Why Walmart Stock's a Buy After Its Beat-And-Raise Quarter
Walmart is the best Dow Jones stock Tuesday after the retail giant's solid earnings report and outlook and Wall Street thinks it's just getting started. Here's what they're saying.
By Joey Solitro Published